Zen Bio Tech Profile
Key Indicators
- Authorised Capital ₹ 1.80 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.15 Cr
as on 16-11-2024
- Company Age 24 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.34 Cr
as on 16-11-2024
- Satisfied Charges ₹ 0.75 M
as on 16-11-2024
- Revenue -28.55%
(FY 2023)
- Profit -35.59%
(FY 2023)
- Ebitda -9.64%
(FY 2023)
- Net Worth 3.89%
(FY 2023)
- Total Assets 15.30%
(FY 2023)
About Zen Bio Tech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.80 Cr and a paid-up capital of Rs 1.15 Cr.
The company currently has active open charges totaling ₹9.34 Cr. The company has closed loans amounting to ₹0.75 M, as per Ministry of Corporate Affairs (MCA) records.
Hema Latha and Erla Narsi serve as directors at the Company.
- CIN/LLPIN
U24230TG2000PTC035169
- Company No.
035169
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Zen Bio Tech Private Limited offer?
Zen Bio Tech Private Limited offers a wide range of products and services, including API (Active Pharmaceutical Ingredients), Pharmaceutical Pellets, Nutraceuticals & Dietary Supplements, Weight Loss Supplement, Antibacterial Drugs, Nutritional Supplements, Multivitamin Supplements, Mineral Supplement, Pharma Ingredients & Raw Materials.
Who are the key members and board of directors at Zen Bio Tech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Erla Narsi  | Managing Director | 23-Aug-2000 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hema Latha | Director | 16-Mar-2005 | Current |
Financial Performance of Zen Bio Tech.
Zen Bio Tech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 28.55% decrease. The company also saw a substantial fall in profitability, with a 35.59% decrease in profit. The company's net worth moved up by a moderate rise of 3.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zen Bio Tech?
In 2023, Zen Bio Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Erla Healthcare Products Private LimitedActive 8 years 9 monthsHema Latha and Erla Narsi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Dec 2021 | ₹5.50 M | Open |
Others Creation Date: 07 Oct 2019 | ₹2.60 M | Open |
Others Creation Date: 07 Feb 2017 | ₹4.65 Cr | Open |
How Many Employees Work at Zen Bio Tech?
Unlock and access historical data on people associated with Zen Bio Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zen Bio Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zen Bio Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
